Pharmaceutical lobbying in Brazil: a missing topic in the public health research agenda
ABSTRACT In the US, where registration of lobbyists is mandatory, the pharmaceutical industry and private health-care providers spend huge amounts of money seeking to influence health policies and government decisions. In Brazil, where lobbying lacks transparency, there is virtually no data on drug...
Main Author: | Francisco José Roma Paumgartten |
---|---|
Format: | Article |
Language: | English |
Published: |
Universidade de São Paulo
|
Series: | Revista de Saúde Pública |
Subjects: | |
Online Access: | http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0034-89102016000200604&lng=en&tlng=en |
Similar Items
-
Assessment of the implementation of accelerated drug marketing registration procedures for antineoplastic and immunomodulating agents in China: based on 2016–2022 review data
by: Yipeng Lan, et al.
Published: (2024-03-01) -
The effects of lobbying on the FDA’s recall classification
by: Yifan Zhou
Published: (2023-06-01) -
The challenges of access to innovative medicines with limited evidence in the European Union
by: Antonio Vallano, et al.
Published: (2023-08-01) -
The case of eculizumab: litigation and purchases by the Brazilian Ministry of Health
by: Rosângela Caetano, et al.
Published: (2020-03-01) -
Lobbying in Polish law and practice
by: Anna Kubiak
Published: (2017-12-01)